| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SLC35F2 |
| Uniprot No | Q8IXU6 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-374 aa |
| 活性数据 | MEADSPAGPGAPEPLAEGAAAEFSSLLRRIKGKLFTWNILKTIALGQMLSLCICGTAITSQYLAERYKVNTPMLQSFINYCLLFLIYTVMLAFRSGSDNLLVILKRKWWKYILLGLADVEANYVIVRAYQYTTLTSVQLLDCFGIPVLMALSWFILHARYRVIHFIAVAVCLLGVGTMVGADILAGREDNSGSDVLIGDILVLLGASLYAISNVCEEYIVKKLSRQEFLGMVGLFGTIISGIQLLIVEYKDIASIHWDWKIALLFVAFALCMFCLYSFMPLVIKVTSATSVNLGILTADLYSLFVGLFLFGYKFSGLYILSFTVIMVGFILYCSTPTRTAEPAESSVPPVTSIGIDNLGLKLEENLQETHSAVL |
| 分子量 | 67.6 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人SLC35F2蛋白的虚构参考文献示例，内容符合常见研究方向：
1. **文献名称**：**"Functional characterization of the human solute carrier SLC35F2 as a nucleotide-sugar transporter"**
**作者**：Smith J. et al.
**摘要**：研究利用昆虫细胞系统表达重组人SLC35F2蛋白，证实其转运UDP-葡萄糖的活性，并分析其在高尔基体糖基化过程中的作用。
2. **文献名称**：**"SLC35F2 overexpression correlates with poor prognosis in glioblastoma multiforme"**
**作者**：Wang L. et al.
**摘要**：通过免疫组化与RNA测序，发现SLC35F2在胶质母细胞瘤中高表达，提示其可能通过调控细胞糖基化促进肿瘤侵袭，或为潜在治疗靶点。
3. **文献名称**：**"Cryo-EM structure of human SLC35F2 reveals substrate recognition mechanism"**
**作者**：Chen H. et al.
**摘要**：解析重组人SLC35F2的冷冻电镜结构，揭示其与底物结合的特定结构域，为设计靶向抑制剂提供结构基础。
4. **文献名称**：**"Knockdown of SLC35F2 disrupts lysosomal function and autophagy"**
**作者**：Yamamoto K. et al.
**摘要**：利用CRISPR/Cas9敲除细胞中SLC35F2基因，导致溶酶体pH失衡及自噬异常，表明其在维持溶酶体稳态中的关键作用。
(注：以上文献为模拟示例，实际研究需参考真实数据库如PubMed或Web of Science。)
**Background of Recombinant Human SLC35F2 Protein**
Solute Carrier Family 35 Member F2 (SLC35F2) is a transmembrane protein belonging to the SLC35 family, which primarily facilitates the transport of nucleotide sugars and other small molecules across cellular membranes. SLC35F2 is localized to the endoplasmic reticulum (ER) and Golgi apparatus, where it is implicated in glycosylation processes by regulating substrate availability for glycan synthesis. While its exact physiological substrates remain under investigation, SLC35F2 has been linked to nucleotide sugar transport, potentially influencing cell signaling, protein trafficking, and extracellular matrix remodeling.
Structurally, SLC35F2 contains 10 transmembrane domains, characteristic of SLC35 transporters, with conserved residues critical for substrate binding and translocation. Studies suggest its involvement in cancer biology: upregulated SLC35F2 expression correlates with tumor progression, possibly through enhanced glycosylation supporting metastasis or drug resistance. Additionally, SLC35F2 interacts with platinum-based chemotherapeutics, hinting at a role in drug uptake or detoxification.
Recombinant human SLC35F2 protein, produced via heterologous expression systems (e.g., HEK293 or insect cells), enables functional studies, including substrate specificity assays and structural analyses. Its recombinant form is pivotal for investigating molecular mechanisms in glycosylation disorders, cancer metabolism, and drug sensitivity. Emerging research highlights SLC35F2 as a potential therapeutic target or biomarker in oncology, though further validation is needed to clarify its precise biological and pathological roles.
×
